Trial Profile
Influence of an Acidic Beverage (Coca-Cola) on the exposure to Imatinib (GLIvec) after major gastrecTomY in patients with Gastrointestinal Stromal Tumors (ABILITY)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Aug 2023
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions
- Acronyms ABILITY
- 28 Jul 2023 According to a Medicenna Therapeutics Media Release, initial data from ABILITYs fifth and sixth dose escalation cohorts will be presented in Q3 2023.Commencement of the ABILITY studys MDNA11 Phase 2 monotherapy arm expected in calendar Q3 2023 and Clinical update expected in calendar Q4 2023.
- 28 Jul 2023 According to a Medicenna Therapeutics Media Release,the company will host a conference call on 9 th Aug 2023 to discuss data from cohorts five and six, recommended dose for monotherapy expansion and details on Phase 2 trial design.
- 28 Jul 2023 According to a Medicenna Therapeutics Media Release, Safety Review Committee clears MDNA11 Cohort 6 dose of 120µg/Kg, Q2W, in the Phase 1 portion of the ABILITY Study.$29.6 million in cash and cash equivalents as of June 30, 2023 provides expected runway through the completion of the ABILITY study and through calendar Q3 2024.